{"id":"NCT02963922","sponsor":"Novo Nordisk A/S","briefTitle":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","officialTitle":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-06","primaryCompletion":"2018-09-10","completion":"2018-09-25","firstPosted":"2016-11-15","resultsPosted":"2019-11-27","lastUpdate":"2020-03-30"},"enrollment":396,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"interventions":[{"type":"DRUG","name":"Liraglutide 3.0 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"liraglutide 3.0 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.","primaryOutcome":{"measure":"Change in Body Weight (%)","timeFrame":"Week 0, week 56","effectByArm":[{"arm":"Liraglutide 3.0 mg","deltaMin":-6,"sd":6},{"arm":"Placebo","deltaMin":-1.5,"sd":5.4}],"pValues":[{"comp":"OG000 vs OG001","p":"< .0001"},{"comp":"OG000 vs OG001","p":"< .0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States","Canada","Germany","Israel","Italy","Mexico","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["32139381"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":195},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Headache","Upper respiratory tract infection"]}}